Vertex Pharmaceuticals Incorporated's total current liabilities is $5B.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Vertex Pharmaceuticals Incorporated (VX1.DE) currently reports a total current liabilities of $5B as of September 2026. That compares with $4.5B in the prior-year period — up 11.7% year over year. Use the charts on this page to explore Vertex Pharmaceuticals Incorporated's total current liabilities history and peer comparisons.
Vertex Pharmaceuticals Incorporated's total current liabilities increased from $4.5B to $5B — a 11.7% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Vertex Pharmaceuticals Incorporated reported $5B in total current liabilities as of September 2026. That compares with $4.5B in the prior-year period — up 11.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total current liabilities of $5B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Vertex Pharmaceuticals Incorporated, and consider following VX1.DE for alerts when major investors trade the stock.
Vertex Pharmaceuticals Incorporated is classified in the Healthcare sector. On total current liabilities, it currently shows $5B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VX1.DE with unrelated industries.